168 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
-acting rhGH products addressing limitations of daily rhGH treatment burden Growing awareness about GH- related diseases Increasing healthcare access
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial-in details and a PIN
8-K
EX-99.1
25azhu
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.1
41lxc31 q6gajd
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.1
q7zxyloawmcmd
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.1
tvg z92p3
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.1
dz51p 80bqlbcw88kg
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.1
cx9qg5 0lfmjz
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.1
is9t9rixz8l1l003
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm